Galectin Therapeutics Inc. (NASDAQ:GALT - Free Report) - Equities researchers at HC Wainwright issued their FY2028 earnings per share estimates for shares of Galectin Therapeutics in a report released on Monday, April 1st. HC Wainwright analyst E. Arce forecasts that the company will earn $3.43 per share for the year. HC Wainwright has a "Buy" rating and a $11.00 price objective on the stock. The consensus estimate for Galectin Therapeutics' current full-year earnings is ($0.66) per share.
Separately, StockNews.com upgraded shares of Galectin Therapeutics from a "sell" rating to a "hold" rating in a research report on Monday.
Read Our Latest Stock Analysis on GALT
Galectin Therapeutics Price Performance
GALT traded up $0.34 during trading on Wednesday, reaching $2.85. 410,355 shares of the stock were exchanged, compared to its average volume of 78,118. Galectin Therapeutics has a 1 year low of $1.28 and a 1 year high of $2.98. The company has a market capitalization of $176.42 million, a price-to-earnings ratio of -3.59 and a beta of 0.84. The business's 50 day moving average price is $1.96 and its two-hundred day moving average price is $1.92.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Osaic Holdings Inc. lifted its position in Galectin Therapeutics by 12.9% during the 2nd quarter. Osaic Holdings Inc. now owns 1,435,557 shares of the company's stock worth $2,067,000 after acquiring an additional 163,797 shares in the last quarter. Geode Capital Management LLC increased its holdings in shares of Galectin Therapeutics by 1.5% during the first quarter. Geode Capital Management LLC now owns 521,678 shares of the company's stock worth $1,096,000 after buying an additional 7,863 shares in the last quarter. Atria Wealth Solutions Inc. acquired a new position in shares of Galectin Therapeutics in the 1st quarter valued at approximately $460,000. Millennium Management LLC boosted its position in Galectin Therapeutics by 7.8% during the fourth quarter. Millennium Management LLC now owns 260,906 shares of the company's stock worth $295,000 after purchasing an additional 18,959 shares during the period. Finally, State Street Corp lifted its position in shares of Galectin Therapeutics by 9.4% during the 1st quarter. State Street Corp now owns 173,740 shares of the company's stock valued at $280,000 after acquiring an additional 14,981 shares during the period. Hedge funds and other institutional investors own 11.68% of the company's stock.
About Galectin Therapeutics
(
Get Free Report)
Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer.
Recommended Stories
Before you consider Galectin Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Galectin Therapeutics wasn't on the list.
While Galectin Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.
Get This Free Report
